Overall Survival was 5.6 months, compared to 5.2 months, an increase of 0.4 months or 2 weeks.
"We are pleased with the results seen in this very difficult to treat patient population," said Kerstin Menander, MD, PhD, head of medical oncology at Peregrine. "Although the median overall survival improvement is modest, further analysis of the data including subgroups shows some very interesting and potentially promising trends.[[ BIOTECH TRICK , ALWAYS SAY THERE IS A SUB POPULATION THAT SHOWED REPSONSE. WHY NOT SHOW THE INTERESTING AND PROMISING TRENDS NOW?]] We look forward to presenting the full data set from this trial later this year at an upcoming scientific meeting." [PROBABLE AT THE SAME MEETING AS RELEASING THE HCV DATA
The pancreatic cancer trial is a randomized, open-label Phase II trial evaluating bavituximab with gemcitabine versus gemcitabine alone in up to 70 patients with previously untreated stage IV pancreatic cancer. The trial allowed the enrollment of patients 18 and older without any age limit, distant organ involvement and ECOG performance status of 0-2. In this trial, bavituximab was generally safe and well tolerated in combination with gemcitabine with similar adverse events occurring in both arms. [NO MECHANISTIC SIDE EFFECTS FOR BAVI]]
"In light of this data, as well as other recent developments in the treatment of pancreatic cancer, we are actively evaluating the next steps for advancing the bavituximab pancreatic program," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "Subgroup analyses from the trial are yielding additional information that we believe will be important in guiding the anticipated future development of bavituximab in this challenging indication. [AGAIN, WHY NOT TELL US THE SUB GROUP ANALYSIS] We are considering potential development pathways [REALLY WISHY WASHY OWRDING HERE] that would allow us to take advantage of bavituximab's broad potential when combined with other cancer agents. We look forward to providing updates as these plans come together." [ YEP, I'M LOOKING FORWAD TO IT TOO]
I was actually preparing to ask about the median OS when I saw your post. Also, like you, was not impressed. If they know about the sub group positives, why not be more specific? I am long, just not a blind long.
to me, it's just another example of showing disrespect to the long investors. Same issue with HCV and cotara. They have the data, they can provide a lot more details. I know they have to spin it as being "exciting" and "promising", but really, these PRs seem geared toward the Day Traders. Not to anyone who has followed the technology.
I don't think a potential partner would be impressed today, and it may call into question the other bavi trials.
Also, I think the ihub board can cease posting the "MOS is not reached" B.S.